

^{*1} The ratio of revenue breakdown by business segment is presented as the composite ratio of the total revenue of Financial Services Business, Asset Management Business, and Biotechnology, Healthcare & Medical Informatics Business

^{*2} Owing to Group company segmentation realignments, the figures compared to FY2020, which reflect the relevant segment changes, are shown as year-over-year figures

FINANCIAL SERVICES BUSINESS

Principal Companies

SBI SECURITIES

SBI Liquidity Market (SBI LM)

SBI FXTRADE (SBI FXT)

SBI VC Trade

SBI MONEYPI AZA

SBI NEOMOBILE SECURITIES

SBI Neotrade Securities

Rheos Capital Works

SBI Benefit Systems

SBI BITS SBI NEO FINANCIAL SERVICES

Japannext

Osaka Digital Exchange

SBI Sumishin Net Bank

Shinsei Bank

Shinsei Financial

API US

Showa Leasing

Shinsei Corporate Investment

SBI Insurance Group

(insurance holding company)

SBI Insurance

SBI Life Insurance

SBI IKIIKI SSI

SBI Nihon SSI

SBI Resta SSI

SBI PRISM SSI

JOGUCHI SAFETY SSI

SBI FinTech Solutions


SBI Remit

SBI Business Solutions

SBI Ripple Asia

B2C2

FY2021 Profit (Loss) before Income Tax Expense of the Major Businesses by Business Area (Based on IFRS)



Note: Including a negative goodwill of ¥263.8 billion due to inclusion of Shinsei Bank in the Financial Services Business from the third quarter of FY2021

ASSET MANAGEMENT BUSINESS

Principal Companies

SBI Investment

SBI FinTech Incubation

SBI VEN CAPITAL

SBI Hong Kong Holdings

SBI (China)

SBI & TH (Beijing) Venture Capital Management

SBI Ventures Malaysia

SBI GLOBAL ASSET MANAGEMENT

Morningstar Japan

SBI Asset Management

Carret Asset Management

SBI SAVINGS BANK

SBI Royal Securities SBI Thai Online Securities


SBI Investment KOREA

SBI Bank PT BNI SEKURITAS SBI LY HOUR BANK SBI Regional Bank Holdings

SBI Estate Finance

SBI Leasing Services

FY2021 Profit before Income Tax Expense of the Major Businesses by Business Area (Based on IFRS)



BIOTECHNOLOGY, HEALTHCARE & MEDICAL INFORMATICS BUSINESS

Principal Companies

SBI ALApharma SBI Biotech

Quark Pharmaceuticals ("Quark")*

SBI Pharmaceuticals SBI Al Anromo

photonamic NX Development

SBI ALApharma Canada Photonics Healthcare Medical Data Vision

* Shares of Quark were completely sold in February 2022

Profit (Loss) before Income Tax Expense of the **Biotechnology, Healthcare & Medical Informatics Business Companies (Based on IFRS)**

(Millions of ven)

		FY2020	FY2021
SBI Biotech		(278)	366
Quark Pharmaceuticals		(4,234)	(68)
5-ALA- related business	SBI Pharmaceuticals	(1,726)	(1,103)
	SBI ALApromo	348	298
	photonamic	71	328
Medical Data Vision (Equity method affiliate)*		36	239

^{*} The results of the previous quarter are recorded as SBI Holdings' equity method, FY2020 includes only the December results after the acquisition of its shares. The SBI Holdings' equity interest in Medical Data Vision's fiscal year ending December 2021 is included in SBI Holdings' results for FY2021

5-ALA-related Products (Products sold as of the end of June 2022)

Ethical drug



ALAGLIO® Divided Granules 1.5g

Health foods and cosmetics



GOLD EX



TOH (Sugar) DOWN

ALA PLUS TOH (Sugar)

DOWN ALACIA



NEMURI (Deep Sleep)





ALA PLUS GOLD HIROU-KAN KEIGEN



ALA PLUS Cosmetic Series